Performance status eligibility requirements and enrollment characteristics in cancer clinical trials leading to US Food and Drug Administration drugs approval (2009-2023).

Eur J Cancer · 2025 · PMC12359999 · PMID 40602341

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

a negative trendp = 0.01actually significant

Of the remaining 279 trials, 72 (25.8 %) allowed the enrollment of poor-PS participants, with a negative trend over the 15-year interval (p = 0.01).

also in 4,201 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.